Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific ant...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/7/8/192 |
id |
doaj-20d317b563534aca992da853d32a7c23 |
---|---|
record_format |
Article |
spelling |
doaj-20d317b563534aca992da853d32a7c232020-11-24T21:07:58ZengMDPI AGJournal of Clinical Medicine2077-03832018-07-017819210.3390/jcm7080192jcm7080192Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for OncologistsKim Tam Bui0Wendy A. Cooper1Steven Kao2Michael Boyer3Chris O’Brien Lifehouse, 119-143 Missenden Road Camperdown, Camperdown, NSW 2050, AustraliaSydney Medical School, University of Sydney, Sydney, NSW 2006, AustraliaChris O’Brien Lifehouse, 119-143 Missenden Road Camperdown, Camperdown, NSW 2050, AustraliaChris O’Brien Lifehouse, 119-143 Missenden Road Camperdown, Camperdown, NSW 2050, AustraliaTargeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.http://www.mdpi.com/2077-0383/7/8/192personalized therapynon-small celllung cancertargeted therapymutationrearrangement |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kim Tam Bui Wendy A. Cooper Steven Kao Michael Boyer |
spellingShingle |
Kim Tam Bui Wendy A. Cooper Steven Kao Michael Boyer Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists Journal of Clinical Medicine personalized therapy non-small cell lung cancer targeted therapy mutation rearrangement |
author_facet |
Kim Tam Bui Wendy A. Cooper Steven Kao Michael Boyer |
author_sort |
Kim Tam Bui |
title |
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists |
title_short |
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists |
title_full |
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists |
title_fullStr |
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists |
title_full_unstemmed |
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists |
title_sort |
targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2018-07-01 |
description |
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC. |
topic |
personalized therapy non-small cell lung cancer targeted therapy mutation rearrangement |
url |
http://www.mdpi.com/2077-0383/7/8/192 |
work_keys_str_mv |
AT kimtambui targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists AT wendyacooper targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists AT stevenkao targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists AT michaelboyer targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists |
_version_ |
1716761343170707456 |